<article xmlns="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle http://dtd.nlm.nih.gov/2.0/xsd/archivearticle.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Tuberculosis (Edinb)</journal-id>
      <journal-title-group>
        <journal-title>Tuberculosis (Edinburgh, Scotland)</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1472-9792</issn>
      <issn pub-type="epub">1873-281X</issn>
      <publisher>
        <publisher-name>Churchill Livingstone</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3158675</article-id>
      <article-id pub-id-type="pmid">21482481</article-id>
      <article-id pub-id-type="publisher-id">YTUBE883</article-id>
      <article-id pub-id-type="doi">10.1016/j.tube.2011.03.005</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Drug Discovery and Resistance</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Effective inhibitors of the essential kinase PknB and their potential as anti-mycobacterial agents</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lougheed</surname>
            <given-names>Kathryn E.A.</given-names>
          </name>
          <email>k.lougheed@imperial.ac.uk</email>
          <xref rid="aff1" ref-type="aff">a</xref>
          <xref rid="fn1" ref-type="fn">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Osborne</surname>
            <given-names>Simon A.</given-names>
          </name>
          <email>simon.osborne@tech.mrc.ac.uk</email>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Saxty</surname>
            <given-names>Barbara</given-names>
          </name>
          <email>barbara.saxty@tech.mrc.ac.uk</email>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Whalley</surname>
            <given-names>David</given-names>
          </name>
          <email>david.whalley@tech.mrc.ac.uk</email>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chapman</surname>
            <given-names>Tim</given-names>
          </name>
          <email>tim.chapman@tech.mrc.ac.uk</email>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bouloc</surname>
            <given-names>Nathalie</given-names>
          </name>
          <email>nathalie.bouloc@tech.mrc.ac.uk</email>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chugh</surname>
            <given-names>Jasveen</given-names>
          </name>
          <email>jasveenchugh@gmail.com</email>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nott</surname>
            <given-names>Timothy J.</given-names>
          </name>
          <email>nott@lunenfeld.ca</email>
          <xref rid="aff3" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Patel</surname>
            <given-names>Dony</given-names>
          </name>
          <email>dony.patel@googlemail.com</email>
          <xref rid="aff3" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Spivey</surname>
            <given-names>Vicky L.</given-names>
          </name>
          <email>vspivey@nimr.mrc.ac.uk</email>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kettleborough</surname>
            <given-names>Catherine A.</given-names>
          </name>
          <email>catherine.kettleborough@tech.mrc.ac.uk</email>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bryans</surname>
            <given-names>Justin S.</given-names>
          </name>
          <email>justin.bryans@tech.mrc.ac.uk</email>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Taylor</surname>
            <given-names>Debra L.</given-names>
          </name>
          <email>debbie.taylor@tech.mrc.ac.uk</email>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Smerdon</surname>
            <given-names>Stephen J.</given-names>
          </name>
          <email>ssmerdo@nimr.mrc.ac.uk</email>
          <xref rid="aff3" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Buxton</surname>
            <given-names>Roger S.</given-names>
          </name>
          <email>rbuxton@nimr.mrc.ac.uk</email>
          <xref rid="aff1" ref-type="aff">a</xref>
          <xref rid="cor1" ref-type="corresp">∗</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>a</label>Division of Mycobacterial Research, MRC National Institute for Medical Research, The Ridgeway, Mill Hill, London, NW7 1AA, United Kingdom</aff>
      <aff id="aff2"><label>b</label>Centre for Therapeutics Discovery, MRC Technology, 1-3 Burtonhole Lane, Mill Hill, London, NW7 1AD, United Kingdom</aff>
      <aff id="aff3"><label>c</label>Division of Molecular Structure, MRC National Institute for Medical Research, The Ridgeway, Mill Hill, London, NW7 1AA, United Kingdom</aff>
      <author-notes>
        <corresp id="cor1"><label>∗</label>Corresponding author. Tel.: +44 20 8816 2225; fax: +44 20 8906 4477. <email>rbuxton@nimr.mrc.ac.uk</email></corresp>
        <fn id="fn1">
          <label>d</label>
          <p>Present address: Department of Life Sciences, Sir Alexander Fleming Building, South Kensington Campus, Imperial College London, London SW7 2AZ, United Kingdom.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <month>7</month>
        <year>2011</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <pub-date pub-type="ppub">
        <month>7</month>
        <year>2011</year>
      </pub-date>
      <volume>91</volume>
      <issue>4</issue>
      <fpage>277</fpage>
      <lpage>286</lpage>
      <history>
        <date date-type="received">
          <day>25</day>
          <month>10</month>
          <year>2010</year>
        </date>
        <date date-type="rev-recd">
          <day>3</day>
          <month>3</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>3</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2011 Elsevier Ltd.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <copyright-holder>Elsevier Ltd</copyright-holder>
        <license>
          <license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>Summary</title>
        <p>PknB is an essential serine/threonine kinase of <italic>Mycobacterium tuberculosis</italic> with possible roles in a number of signalling pathways involved in cell division and metabolism. We screened a library of &gt;50,000 compounds for inhibitors of the <italic>in vitro</italic> phosphorylation of GarA (Rv1827) by PknB and identified a number of inhibitors. A program of synthetic medicinal chemistry was subsequently conducted around one class of inhibitors and was successful in generating ATP competitive inhibitors with potency in the nanomolar range. Compounds in this class showed cross-reactivity with the related <italic>M</italic>. <italic>tuberculosis</italic> kinase, PknF, but not with PknG in an <italic>in vitro</italic> autophosphorylation assay. These synthesised inhibitors were able to prevent the growth of <italic>M. tuberculosis</italic> in an Alamar blue assay and in an intracellular model of infection, but only in the micromolar range. We attempted to determine if cell wall permeability was an explanation for the discrepancy between the potent <italic>in vitro</italic> compared with relatively poor <italic>in vivo</italic> activity, but found no evidence that the activity of the inhibitors could be improved by weakening the cell wall. Despite a number of drug discovery efforts attempting to develop inhibitors against PknB, it is yet to be reported that any such inhibitors prevent mycobacterial growth at submicromolar concentrations.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>
          <italic>Mycobacterium tuberculosis</italic>
        </kwd>
        <kwd>Kinases</kwd>
        <kwd>PknB</kwd>
        <kwd>Inhibitors</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1">
      <label>1</label>
      <title>Introduction</title>
      <p><italic>Mycobacterium tuberculosis</italic> remains one of the world’s most devastating pathogens, with more than 13 million people suffering from an active tuberculosis infection and 1.8 million resulting deaths in 2008 alone.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> The emergence of multi-drug and extensively drug resistant strains has highlighted the need for new drugs to treat tuberculosis. Recent studies have focused on finding new pathways vulnerable to inhibition by small molecules and previously unexploited by drug discovery efforts. The inhibition of signalling pathways both in <italic>M. tuberculosis</italic> and the host may yield new classes of drug targets and a large amount of recent work has focused on developing this further.</p>
      <p>Target based drug discovery, in which there is <italic>in vitro</italic> high throughput screening of a large number of small molecules against a validated target, has been used on a number of occasions to search for new anti-tuberculosis agents. We sought to find inhibitors of an essential <italic>M. tuberculosis</italic> serine/threonine protein kinase, PknB. Kinases are attractive as drug targets due to the range of crucial cellular processes in which they are involved. There has been much interest in developing ATP competitive kinase inhibitors for the treatment of cancer, a hallmark of which is often aberrant kinase activity. A large number of small molecule kinase inhibitors have been developed as potential anti-cancer drugs and there is a huge amount of interest in developing kinase inhibitors to treat a range of conditions.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Kinase-focused libraries of small molecule inhibitors have been built-up as a result of these studies and a large amount of knowledge has been gained on the action of kinase inhibitors. The early success stories from the development of eukaryotic kinase inhibitors suggested that similar drugs could be developed to treat bacterial infections. The <italic>M. tuberculosis</italic> serine/threonine protein kinases (STPKs) are attractive targets partly because of the inferred importance of serine/threonine phosphorylation in <italic>M. tuberculosis: M. tuberculosis</italic> is unique within the bacterial world in having a much higher number of STPKs compared to the more common two-component signalling systems.<xref rid="bib3 bib4 bib5 bib6" ref-type="bibr"><sup>3–6</sup></xref> <italic>Mycobacterium leprae</italic>, during extensive reductive evolution, has lost all but four of these kinases: PknA, PknB, PknG and PknL.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> PknA and PknB are essential in <italic>M. tuberculosis,</italic><xref rid="bib8 bib9 bib10" ref-type="bibr"><sup>8–10</sup></xref> while PknG has been reported to be involved in survival in the macrophage, either as a result of a role in glutamate metabolism<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> or via modulation of host cell trafficking pathways.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref></p>
      <p>Previous studies have focused on the potential of PknB and PknG as drug targets in <italic>M. tuberculosis</italic>, although the majority have reported significantly less impressive activity against whole cells than against the purified protein <italic>in vitro</italic>.<xref rid="bib8 bib12 bib13 bib14" ref-type="bibr"><sup>8,12–14</sup></xref> Despite this, there can be no doubt, from a number of lines of evidence, that PknB carries out function(s) essential to <italic>M. tuberculosis</italic>, and possesses a number of properties that suggest it is suitable for development of novel drugs: a crystal structure has also been determined for PknB<xref rid="bib15 bib16" ref-type="bibr"><sup>15,16</sup></xref> and the kinase domain exhibits less than 30% similarity with eukaryotic kinases, which has positive implications for developing a drug specific for the bacterial kinases and not those of the host. The <italic>pknB</italic> gene (Rv0014c) is part of an operon highly conserved among the actinomycetes and also encoding <italic>pknA</italic>, the other essential kinase; <italic>pstP</italic>, a phosphoserine/threonine phosphatase; <italic>rodA</italic>, a cell division protein; <italic>pbpA</italic>; a protein involved in peptidoglycan biosynthesis; and two genes (<italic>fhaB</italic> and <italic>fhaA</italic>) coding for forkhead-associated proteins. Over-expression or depletion of this kinase results in gross changes in cell morphology, likely a result of the role of PknB in the phosphorylation-mediated regulation of a number of proteins involved in cell wall biosynthesis.<xref rid="bib10 bib17 bib18" ref-type="bibr"><sup>10,17,18</sup></xref> In addition, both PknB and PknG are known to phosphorylate a protein involved in the regulation of glutamate metabolism,<xref rid="bib19 bib20 bib21" ref-type="bibr"><sup>19–21</sup></xref> suggesting that an inhibitor of one or both of these kinases could also impact on the ability of <italic>M. tuberculosis</italic> to adequately regulate its central metabolic processes. Targeting of these bacterial kinases would therefore be a way of inhibiting evolutionarily-conserved steps in central metabolic processes.</p>
      <p>We screened for small molecule inhibitors of PknB and, as a result of a medicinal chemistry program (manuscript in preparation), our lead compounds were able to inhibit PknB activity <italic>in vitro</italic> in the nanomolar range. However, the potency of our compounds against whole cells in culture or in a macrophage model of infection was two orders of magnitude lower than expected from the <italic>in vitro</italic> potency. An often suggested explanation for low anti-tuberculosis activity is the problem of cell wall permeability. Since the <italic>M. tuberculosis</italic> cell wall presents an extremely hydrophobic barrier which can impede the entry of drugs into the cell, we sought to determine if cell wall permeability might explain the difficulties in improving the potency of our PknB inhibitors. In addition, we investigated the role of efflux pumps, protein binding in the assay media and inhibitor specificity as alternative explanations.</p>
    </sec>
    <sec sec-type="materials|methods" id="sec2">
      <label>2</label>
      <title>Materials and methods</title>
      <sec id="sec2.1">
        <label>2.1</label>
        <title>Compounds</title>
        <p>Compounds for the high throughput screening included the MRCT compound collection comprising 45,000 diverse templates from commercially available collections, as well as 6400 kinase-focused templates (Biofocus DPI, Cambridge, UK) selected on the basis of bio-informatics provided by the crystal structure of PknB and other serine/threonine kinases. Focused libraries, based around compounds identified from the initial screen, were subsequently generated by synthetic medicinal chemistry.</p>
      </sec>
      <sec id="sec2.2">
        <label>2.2</label>
        <title>Protein expression and purification</title>
        <p>GarA was expressed in <italic>Escherichia coli</italic> and purified as described.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> The 279 residue kinase domain of PknB and the 292 residue kinase domain of PknF were expressed as 3C-protease cleavable GST-fusions in <italic>E. coli</italic> Rosetta 2 (DE3) pLysS cells. The proteins were purified with glutathione Sepharose 4B resin (GE Healthcare) and the GST-tag cleaved from the protein prior to elution using 3C protease (GE Healthcare).</p>
      </sec>
      <sec id="sec2.3">
        <label>2.3</label>
        <title>High throughput protein kinase assays</title>
        <p>A non-radioactive PknB kinase assay was developed to follow ATP depletion during the PknB-catalyzed phosphorylation of GarA (Rv1827). The Promega ‘Kinase Glo’ assay kit was used to measure levels of phosphorylation via detection of the remaining ATP after the completion of the kinase reaction. Briefly, luciferase and beetle luciferin were introduced to the reaction mix and, in the presence of Mg<sup>2+</sup>, ATP and oxygen, the oxygenation of luciferin generates one photon of light per turnover. PknB activity is inversely proportional to the intensity of the luminescence signal. Using this assay format the K<sub>m</sub> of ATP was determined to be 1.5 μM and ATP was used at this concentration for screening.</p>
        <p>The following reaction mix was prepared: 0.15 μM PknB and 5 μM Rv1827 in reaction buffer (50 mM Tris–HCl, 150 mM NaCl, 1 mM DTT and 0.01% Triton X-100). The assay was carried out in 22 μl volumes in 384-well white plates (Matrix, 4316). A Beckman Biomek Fx liquid handling robot was used to dispense premixed reaction mix into the wells and the 2 μl of the compound/DMSO added to a final concentration of 10 μM/1% DMSO. The plates were incubated for 30 min and the reaction initiated with the addition of 1 mM MnCl<sub>2</sub>/1.5 μM ATP using the Perkin Elmer Flexdrop non-contact liquid dispenser. The reaction was stopped after 20 min with the addition of 22 μl Kinase Glo reagent and luminescence read with a BMG Polarstar reader. Control wells with and without PknB were included on every plate in columns 1, 2 and 23, 24 and were used to calculate Z′ values.<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> Data from any plates with Z′&lt;0.5 were rejected and were repeated.</p>
      </sec>
      <sec id="sec2.4">
        <label>2.4</label>
        <title>Strains and growth conditions</title>
        <p><italic>M. tuberculosis</italic> H37Rv, <italic>Mycobacterium smegmatis</italic> mc<sup>2</sup>155, <italic>M. smegmatis</italic> Δ<italic>fbpA</italic> (gift from C. Thompson), and <italic>M. tuberculosis</italic> Δ<italic>ompA</italic> (gift from P. Draper) cultures were grown at 37 °C in Dubos broth supplemented with 0.05% (vol/vol) Tween 80, 0.2% (vol/vol) glycerol, and 4% (vol/vol) Dubos medium albumin (Becton Dickinson). <italic>M. smegmatis</italic> strains were grown either in 5 ml volumes in 20 ml universals or in 50 ml volumes in 250 ml flasks, incubated in an orbital shaker at 150 rpm at 37 °C. <italic>M. tuberculosis</italic> was grown either in 100 ml volumes in a Bellco roll-in incubator (2 rpm) or in 10 ml volumes in static universals. Kanamycin was used at a final concentration of 25 μg ml<sup>−1</sup>. <italic>M. tuberculosis</italic> was grown on 7H11 supplemented with 10% OADC enrichment (Middlebrook) and 0.5% (vol/vol) glycerol.</p>
      </sec>
      <sec id="sec2.5">
        <label>2.5</label>
        <title><italic>M. tuberculosis</italic> minimum inhibitory concentration (MIC) determination</title>
        <p>MICs were determined for <italic>M. tuberculosis</italic> using a 96-well plate method with Alamar blue, as described previously.<xref rid="bib24 bib25" ref-type="bibr"><sup>24,25</sup></xref> A modified version of the assay used <italic>M. smegmatis</italic> with a 3 day incubation. The cell wall weakening and efflux pump inhibition assays were modifications of the Alamar blue assay, as described in the results. Z′ values were used as a measure of assay quality, using the following formula: Z′ = 1–3 × SSD/R, where SSD is the sum of the Standard Deviation of the negative controls and Standard Deviation of the positive controls, and R is the mean of the maximum signal control minus the mean of the negative signal control.<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref></p>
      </sec>
      <sec id="sec2.6">
        <label>2.6</label>
        <title>Intracellular activity of PknB inhibitors in a macrophage infection by <italic>M. tuberculosis</italic></title>
        <p>Intracellular inhibition was tested in murine bone marrow-derived macrophages at a range of concentrations as previously described.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> Briefly, monocytes were isolated from Balb/c bone marrow and differentiated with L-cell supernatant for 5–7 days. The macrophages were infected with <italic>M. tuberculosis</italic> with an MOI of 0.5 bacteria: 1 macrophage for 4 h, and the infection incubated in the presence of various concentrations of the inhibitors for 5 days. At this point, the macrophages were lysed with dH<sub>2</sub>0 + 0.05% Tween 80 and plated for CFU enumeration. Prior to the infection, the compounds were tested to rule out any effect of toxicity against the macrophages. Alamar blue was used to determine macrophage viability after incubation with the inhibitors (not shown).</p>
      </sec>
      <sec id="sec2.7">
        <label>2.7</label>
        <title>Kinase autophosphorylation assay</title>
        <p><italic>In vitro</italic> autophosphorylation of PknA, PknB, PknG and PknF (1 μg) was carried out in 20 μl reaction mixture containing 2.5 μl buffer P (25 mM Tris–HCl, pH 7.0, 1 mM dithiothreitol, 5 mM MgCl<sub>2</sub>, 1 mM EDTA). The reaction was initiated with the additional of 0.08 μCi [γ-<sup>32</sup>P] ATP and incubated at 37 °C for 30 min. The reaction was terminated with the addition of SDS-PAGE sample buffer and heating the mixture at 100 °C for 5 min. The reaction mixtures were analyzed by SDS-PAGE. The gels were soaked in 20% tricholoroacetic acid for 10 min at 90 °C and dried. Radioactive proteins were visualized by autoradiography and quantified by Phosphorimage analysis using a STORM 840 Optical Scanner System and ImageQuant (version 5.2, Molecular Dynamics, Sunnyvale, CA). Images were adjusted for contrast and brightness using Adobe Photoshop.</p>
      </sec>
      <sec id="sec2.8">
        <label>2.8</label>
        <title>Radioactive competition assay</title>
        <p>Reactions were set up in a volume of 17 μl kinase buffer (50 mM Tris–HCl pH7.2, 1 mM DTT, 0.01% TX-100) containing 100 nM purified PknB and 3 μM purified Rv1827 and increasing amounts of each inhibitor diluted in neat DMSO (from 0.03 μM to 100 μM) in polypropylene U-bottomed 96 well plates. The reactions were started by the addition of 5 μl of solutions containing MnCl<sub>2</sub> and ATP at K<sub>m</sub> or 50xK<sub>m</sub>, to achieve final concentrations of 1 mM MnCl2 with 1.5 μM ATP and 0.1 μCi <sup>33</sup>P or 75 μM ATP and 1 μCi <sup>33</sup>P.</p>
        <p>After incubating for 70 min at room temperature, reactions were terminated by the addition of 20 μl 50% orthophosphoric acid. Reactions were then transferred to a 96 well glass filter capture plate (GF/C) and unbound <sup>33</sup>P was washed away with 200 μl 1.5% orthophosphoric acid, using a Tomtec Harvester 9600. After drying overnight at room temperature, 25 μl scintillant was added to each well and quantification of Rv1827 phosphorylation achieved by detecting incorporated <sup>33</sup>P with the PE Topcount.</p>
      </sec>
      <sec id="sec2.9">
        <label>2.9</label>
        <title>Kinase profiling against a panel of mammalian kinases</title>
        <p>This was carried out using a <sup>33</sup>P-ATP filter-binding assay<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> on a panel of 70 mammalian kinases at the National Centre for Protein Kinase Profiling in the MRC Protein Phosphorylation Unit at the University of Dundee.</p>
      </sec>
      <sec id="sec2.10">
        <label>2.10</label>
        <title>Docking studies with PknB inhibitors</title>
        <p>The mitoxantrone bound crystal structure (PDB:<ext-link ext-link-type="uri" xlink:href="pdb:2FUM">2FUM</ext-link>) was selected for docking studies owing to its greater suitability in terms of ligand-induced binding site architecture as compared to the ATP bound structure (PDB:1MRU). Protein preparation, grid generation and docking (GlideSP) were all carried out using the Schrodinger molecular modelling suite (Schrodinger LLC: New York. <ext-link ext-link-type="uri" xlink:href="http://www.schrodinger.com">http://www.schrodinger.com</ext-link>).</p>
      </sec>
    </sec>
    <sec id="sec3">
      <label>3</label>
      <title>Results</title>
      <sec id="sec3.1">
        <label>3.1</label>
        <title>High throughput screening for PknB inhibitors</title>
        <p>PknB has been previously validated as a suitable target for drug discovery and we sought to identify small molecule inhibitors targeted against this kinase. A number of potential substrates for PknB were tested, with GarA (Rv1827) being chosen as the most strongly phosphorylated protein in our assay. GarA has been described as an <italic>in vivo</italic> target for both PknB and PknG<xref rid="bib19 bib20" ref-type="bibr"><sup>19,20</sup></xref> and interaction with this target is known in some detail.<xref rid="bib22 bib27" ref-type="bibr"><sup>22,27</sup></xref> A non-radioactive PknB kinase assay was developed to follow ATP depletion during the PknB-catalyzed phosphorylation of GarA. Substrate K<sub>m</sub>s were determined for both ATP (1.5 μM) and Rv1827 (&gt;20 μM). The K<sub>m</sub> ATP concentrations and an excess of peptide (5 μM) were selected to achieve a robust assay window &gt;0.5 within the linear phase of the reaction, maximizing sensitivity to ATP competitive inhibitors.</p>
        <p>In total ∼54,000 compounds were screened against PknB. The compound collection was sourced by MRCT from commercial suppliers. Drug-like filters to assess both physicochemical properties and known toxicophores were applied to the selection process. The MRCT library comprised ∼44,000 diverse compound collection and ∼9000 kinase-focused collection (targeting ATP binding site). In addition, ∼1000 natural products (Phytoquest) were screened. The average Z′ was 0.76 and a confirmed hit rate of 0.14% was observed. In total, 76 compounds confirmed IC<sub>50</sub> in the range 1–200 μM.</p>
        <p>Limitations of the Kinase glo assay format did not permit detailed enzyme kinetics to be performed. However using a radioactive assay, a number of compounds were assessed for ATP competitiveness by measuring IC<sub>50</sub> at a high (75 μM) and a low (1.5 μM, Km) ATP concentration. From the Cheng–Prussoff equation<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> we would predict that for an ATP competitive inhibitor, a 25-fold shift in IC<sub>50</sub> would be seen between ATP at K<sub>m</sub> (1.5 μM) and 50XK<sub>m</sub> (75 μM). Five compounds from the series, including the original screen hit, with a range of potencies 50–1000 nM in the primary assay were selected. Fold shifts in the range 15.5–32 were observed for all compounds, consistent with an ATP competitive mechanism. It was expected that, due to the higher ATP concentration in the cells compared to the <italic>in vitro</italic> assay, a shift in MIC compared to IC<sub>50</sub> enzyme activity would be observed. However, a consistent shift was not observed.</p>
        <p>Docking studies (<xref rid="fig1" ref-type="fig">Figure 1</xref>) indicate that the compounds should be ATP competitive. They bind to the hinge region via two H-bonds between the ligand core and the peptide backbone of Val95 along with an additional H-bond via the ligand pyrazole NH to the peptide carbonyl of Glu93. Numerous Van Der Waals contacts contribute to binding, most notably between the ligand cyclopropyl group in the hydrophobic pocket towards the Met92 gatekeeper and also via extensive contact along the glycine rich loop at the entrance to the binding site.</p>
      </sec>
      <sec id="sec3.2">
        <label>3.2</label>
        <title>Anti-tuberculosis activity of lead compounds</title>
        <p>Compounds that showed potent activity against PknB <italic>in vitro</italic>, no cytotoxicity and good selectivity against a panel of mammalian kinases, were tested in an <italic>M. tuberculosis</italic> Alamar blue MIC assay. Briefly, 2-fold dilutions of the inhibitors were incubated at 37 °C with approximately 1 × 10<sup>5</sup> cells per well in 96-well microplates for 7 days. Untreated <italic>M. tuberculosis</italic> and media only controls were included on every plate, and the control drugs isoniazid, streptomycin and ethambutol were tested in parallel with each batch of PknB inhibitors to ensure that the assay was reproducible. The Alamar blue reagent was added on the final day of the incubation, and the fluorescence measured at the completion of the experiment. A 90% inhibition of fluorescence compared to the untreated control was chosen as the cutoff for the determination of inhibitory concentrations. The statistical parameter, Z′-factor, was used as a measure of assay quality, with a score greater than 0.75 taken as an indication of good data.</p>
        <p>MICs were determined for more than 100 compounds, with a range of MICs being observed varying between inactive at 250 μM to inhibitory at 8–16 μM. The compounds were also tested against <italic>M. smegmatis</italic> (data not shown) with a generally good agreement between the two assays. This confirms previously published experiments (e.g.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref>) which have suggested that testing compounds against <italic>M. smegmatis</italic> is a good model for TB drug discovery. There was a poor correlation between IC<sub>50</sub> against the purified recombinant protein and anti-<italic>M. tuberculosis</italic> MIC, with the majority of compounds proving to be inactive against the whole cells. The lack of correlation between protein and whole cell activity is illustrated in <xref rid="fig2" ref-type="fig">Figure 2</xref>. Despite extensive rounds of chemistry, unfortunately it was not possible to reduce the <italic>M. tuberculosis</italic> MICs below the 10 μM level.</p>
      </sec>
      <sec id="sec3.3">
        <label>3.3</label>
        <title>Intracellular activity of PknB inhibitors against <italic>M. tuberculosis</italic> in a bone marrow derived macrophage model of infection</title>
        <p>A subset of compounds was chosen for further investigation. The key criteria in this selection included reasonable activity against <italic>M. tuberculosis in vitro</italic>, a low MIC to IC<sub>50</sub> ratio as a possible indication of good cell wall permeability, good selectivity against a panel of human kinases and good physicochemical parameters, including moderate logD and low hydrogen bond donor count, both of which are requirements for good membrane permeability. The intracellular activity of these compounds against <italic>M. tuberculosis</italic> in a bone marrow derived macrophage model of infection was tested.</p>
        <p>The compounds showed a dose dependant inhibition of intracellular <italic>M. tuberculosis</italic>, although a number of the compounds were not able to inhibit 99% growth compared to the untreated control (chosen as the cutoff for determining intracellular inhibition). <xref rid="fig3" ref-type="fig">Figure 3</xref> shows the inhibition of intracellular growth by the 12 PknB inhibitors chosen for further investigation. At the lowest concentration tested, 2.5 μM, none of the compounds were able to inhibit growth by more than 99% of the control. A number of the compounds were active at the higher concentrations of 10 and 20 μM. While concentrations up to 100 μM were tested, these are not shown due to a number of the compounds proving to have toxic effects against the macrophages, possibly due to inhibition of host kinases.</p>
        <p>A summary of the data is shown in <xref rid="tbl1" ref-type="table">Table 1</xref>. Little correlation between intracellular activity and whole cell inhibition was found.</p>
      </sec>
      <sec id="sec3.4">
        <label>3.4</label>
        <title>Role of cell wall permeability and efflux on inhibitor MIC</title>
        <p>Poor anti-tuberculosis activity by compounds that are potent in the <italic>in vitro</italic> protein assay is often attributed to impermeability of the <italic>M. tuberculosis</italic> cell wall. <italic>M. tuberculosis</italic> has a thick and ‘waxy’ cell wall, which limits the ability of compounds to penetrate and reach the cytoplasm.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> Much of the impermeability stems from the unique mycolic acid layer. While little is known about the specific properties of small molecules that enable them to diffuse across the <italic>M. tuberculosis</italic> cell wall, it is possible to modify certain functional groups of the compounds in ways that will hopefully improve entry into the cytoplasm. For example, modifications were made to our more active compounds in an attempt to vary the compounds’ LogP values and increase their hydrophobicity (to be discussed in a separate medicinal chemistry paper). In one case, it was possible to improve the MIC/IC<sub>50</sub> ratio using this approach. However, the resulting activity of the compounds against <italic>M. tuberculosis</italic> was still poor. Before embarking on further chemistry with the hope of improving cell penetration, we attempted to determine whether cell wall permeability truly was a major contribution to low MIC values through the use of several cell wall-weakened models with the subset of inhibitors shown in <xref rid="fig3" ref-type="fig">Figure 3</xref>.</p>
        <p>A number of chemicals and antibiotics were tested, including Triton X-100, glycine, lysozyme, isoniazid and ethambutol. There have been previous reports of sub-lethal concentrations of antibiotics targeted to the cell wall being able to enhance permeability of certain compounds.<xref rid="bib31 bib32" ref-type="bibr"><sup>31,32</sup></xref> In particular, ethambutol has been demonstrated to enhance the activity of rifampicin, streptomycin and isoniazid against drug resistant strains.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> In our experiments, the cell wall weakening agent was used at 0.5 MIC in conjunction with the PknB inhibitors to determine whether the inhibitors were better able to inhibit <italic>M. tuberculosis</italic> in the presence of a weakened cell wall. As a control, we demonstrated that the MIC of rifampicin was reduced by 4-fold in the presence of sub-inhibitory concentrations of ethambutol, confirming published data that reported that accumulation of and sensitivity to rifampicin is enhanced by ethambutol.<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> We tested a number of compounds, including the subset of 12 active compounds and a number that were previously inactive against <italic>M. tuberculosis</italic>. Several compounds were able to inhibit <italic>M. tuberculosis</italic> in the presence of ethambutol when they had been previously inactive. This implied that cell wall permeability was, indeed, a problem for some structural families. However, the MICs of the most efficacious compounds were not improved by ethambutol treatment.</p>
        <p>In addition to the ethambutol cell-wall weakened model, we wanted to use a more defined model. An <italic>M. smegmatis fbpA</italic> mutant has been shown to possess increased sensitivity to a number of antibiotics due to alterations in its cell wall.<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> FbpA is involved in mycolic acid biosynthesis and the mutant has a loss of cell wall hydrophobicity compared with the wild type. We tested the sensitivity of this mutant to the PknB inhibitors and, in agreement with the ethambutol data, there was no improvement in inhibition with a weakened cell wall. In comparison, vancomycin MIC was improved by 16-fold and erythromycin by 8-fold. This effect was specific to certain antibiotics as the MICs and streptomycin and ethambutol were not improved in the assay.</p>
        <p>After testing the role of the mycolic acid layer in drug permeability, we sought also to investigate other possible paths of entry into the cell. Antibiotics can either diffuse across the cell wall, a possibility investigated in the experiments detailed above, or alternatively may enter through hydrophilic channels. Porins in the mycobacterial outer membrane are required for the diffusion of hydrophilic solutes and are the route of entry for small and hydrophilic antibiotics such as isoniazid and ethambutol.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> It has been demonstrated that an <italic>mspA</italic> porin deletion mutant of <italic>M. smegmatis</italic> has a multi-drug resistant phenotype to antibiotics including ampicillin.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> Although <italic>M. tuberculosis</italic> does not encode Msp-like proteins, expression of <italic>M. smegmatis</italic> MspA in <italic>M. tuberculosis</italic> enhances antibiotic sensitivity<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> and an <italic>M. tuberculosis</italic> outer membrane channel-forming protein has been demonstrated to restore antibiotic sensitivity to a <italic>M. smegmatis mspA</italic> mutant.<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> One of the best understood porins in <italic>M. tuberculosis</italic> is OmpA, that has been linked to the diffusion of pyrazinamide across the cell wall.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> <italic>M. tuberculosis ompA</italic> mutants have not been reported to have an antibiotic resistant phenotype similar to <italic>M. smegmatis mspA.</italic> Therefore, we tested the sensitivity of the mutant to a number of antibiotics compared to the wild type strain. Unlike <italic>M. smegmatis mspA, M. tuberculosis ompA</italic> did not have increased sensitivity to the small, hydrophilic antibiotics tested. However, it did show a slightly increased resistance to the large antibiotics vancomycin and erythromycin. This result was also observed for <italic>M. smegmatis mspA</italic>, despite both of these antibiotics being too large to enter the cell via porins. It is likely that alterations in the cell wall have a knock-on effect on entry of large antibiotics into the cell. This experiment does not provide any evidence that small antibiotics enter <italic>M. tuberculosis</italic> via OmpA channels, but we cannot rule out that OmpA is involved in the uptake of other antibiotics not tested. We also tested the <italic>ompA</italic> mutant with the PknB inhibitors and observed that the majority of them were equally active against the wild type and mutant.</p>
        <p>The activity of efflux pump inhibitors has been shown to play a role in the acquired drug resistance of <italic>M. tuberculosis</italic> for a number of antibiotics,<xref rid="bib41 bib42 bib43 bib44" ref-type="bibr"><sup>41–44</sup></xref> due to the upregulation of efflux pumps in drug resistant strains. It has been suggested that the use of efflux pump inhibitors in conjunction with anti-tuberculosis therapy could be used to reverse the efflux pump-mediated drug resistance in some infections.<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> There is also some evidence that efflux plays a role in the intrinsic drug resistance of mycobacteria.<xref rid="bib46 bib47 bib48" ref-type="bibr"><sup>46–48</sup></xref> Therefore, we tested whether the addition of sub-inhibitory concentrations of the efflux pump inhibitors reserpine and verapamil to our assay would improve the PknB inhibitor MICS. No change was observed in MIC at either 20 or 40 μg/ml of either efflux pump inhibitor, while the MIC of the ethidium bromide control was decreased by 4-fold. This is perhaps not surprising due to the observation that the effect of efflux inhibitors is most dramatic when there is overexpression or upregulation of efflux pumps, rather than against wild type levels.<xref rid="bib34 bib45" ref-type="bibr"><sup>34,45</sup></xref></p>
      </sec>
      <sec id="sec3.5">
        <label>3.5</label>
        <title>Specificity of PknB inhibitors</title>
        <p>Attempts to select resistant mutants of the 12 most potent PknB inhibitors were unsuccessful, possibly due to either the high MICs of the compounds, or non-specific activity of the inhibitors. We plated 5 × 10<sup>9</sup> <italic>M. tuberculosis</italic> directly on to media containing 2, 4 and 8×MIC inhibitors as well as pre-growing the cells on 0.5 and 1×MIC before replating on the above concentrations. Neither method generated any resistant colonies. This, combined with the lack of correlation between MIC and activity in the <italic>in vitro</italic> protein assay led us to consider whether the inhibitors are truly targeting PknB. It is possible that some of the anti-tuberculosis activity of the inhibitors is due to off-target activity, meaning that further PknB-focused chemistry based around these structural families is unlikely to lead to an improvement in MIC. Alternatively, despite good selectivity over mammalian kinases, the inhibitors could be binding to a number of the other more closely related <italic>M. tuberculosis</italic> kinases, and it is possible that the inhibitor is being sequestered away from PknB by its activity against any of the eight non-essential kinases in <italic>M. tuberculosis</italic>.</p>
        <p>We used an <italic>in vitro</italic> radioactivity based screen to measure the ability of the compounds to inhibit autophosphorylation of some of the other <italic>M. tuberculosis</italic> kinases. PknA, the other essential kinase, was tested but, due to high levels of stable phosphorylation of this kinase following purification, it was not sufficiently active in the assay. Due to the essential nature of PknA, we were not concerned about possible cross-reactivity of the PknB inhibitors with this kinase. In fact, this could be advantageous for the development of a TB drug. We also tested the ability of the inhibitors to inhibit PknF and PknG autophosphorylation. PknG is a soluble kinase while PknF is membrane-associated like PknB; both are non-essential.</p>
        <p>It was observed that there is a high degree of cross-reactivity between the PknB inhibitors and PknF, the other membrane-associated kinase tested. However, PknG was less strongly inhibited at the concentrations tested (<xref rid="fig4" ref-type="fig">Figure 4</xref>). A possible explanation for this is the 39.5% sequence identity shared between PknB and PknF compared to only 27.3% between PknB and PknG.</p>
      </sec>
    </sec>
    <sec id="sec4">
      <label>4</label>
      <title>Discussion</title>
      <p>PknB has been shown to be an essential protein in <italic>M. tuberculosis,</italic><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> and is proposed to be involved in a number of vital pathways. Initially, it was implicated as having a role in cell division due to its chromosomal location within an operon containing genes known to be important for these processes. Depletion or overexpression of PknB results in gross changes in cell morphology, and some of its identified substrates are known to be important for cell wall and division-related functions.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> The cell wall is known to be a strong target for anti-tuberculosis drugs, due to its importance for the survival of the pathogen and its uniqueness. PknB is most strongly expressed during exponential growth<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> and upon infection of a THP-1 macrophage cell line,<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref> suggesting that the kinase is involved in general growth and important during an infection. More recently, it has been seen that one of PknB’s substrates, GarA, has a role in intermediary metabolic processes. GarA negatively regulates two proteins involved in metabolism, 2-hydroxy-3-oxoadipate synthase and glutamate dehydrogenase and is itself negatively regulated via phosphorylation by PknB.<xref rid="bib20 bib21 bib22" ref-type="bibr"><sup>20–22</sup></xref> Interestingly, GarA is also known to be phosphorylated <italic>in vivo</italic> by PknG on a neighbouring threonine to that phosphorylated by PknB.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref></p>
      <p>The known functions of PknB detailed above do suggest that this kinase would be a strong candidate for an anti-tuberculosis drug. We found a number of inhibitors able to inhibit PknB <italic>in vitro</italic> with IC<sub>50</sub>s in the 20 nM range. The MICs of these inhibitors against <italic>M. tuberculosis</italic> were found to be in the 16 μM to inactive range, despite several rounds of compound optimization. Some shift in MIC compared to IC<sub>50</sub> was expected due to higher intracellular concentrations of ATP leading to competition. However, a consistent shift was not observed across the series, suggesting additional mechanisms are involved in the poor activity against whole cells. It should also be noted that the intracellular concentration of ATP in <italic>M. tuberculosis</italic> is in the micromolar range<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> (A. Chang, unpublished data), which is significantly lower than that the accepted millimolar concentrations for mammalian cells. The poor MIC to IC<sub>50</sub> ratios appear to be a similar result to the published data of other groups who have also attempted to develop PknB or PknG inhibitors.<xref rid="bib8 bib12 bib13 bib14" ref-type="bibr"><sup>8,12–14</sup></xref> This poor activity was evident even in an intracellular assay.</p>
      <p>We investigated the role of cell wall permeability, either diffusion through the hydrophobic cell wall or diffusion through hydrophilic channels, and found no evidence that this was a limiting step in the action of the inhibitors. We also investigated the role of efflux and observed that inhibitor activity was not improved in an efflux pump inhibited model.</p>
      <p>A possibility is that the more potent inhibitors, which were chosen for compound optimization, were not targeting PknB in the cells. A similar problem was described by Payne et al.<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> in their review of GlaxoSmithKline’s 7 years of antibacterial high throughput screen (HTS) research. They attributed the antibacterial activity of some of their lead compounds to non-specific membrane interactions that led to cell lysis. We did attempt to determine the <italic>in vivo</italic> target of the inhibitors by generating resistant mutants, however this proved unsuccessful. In a previous study, Fernandez et al. used <italic>M. smegmatis</italic> overexpressing PknB to demonstrate that an increase in PknB levels was able to increase resistance to their PknB inhibitors.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> However, they were only able to see a modest 2-fold increase in resistance compared to the control strain. Our attempts to perform a similar experiment in <italic>M. tuberculosis</italic> proved difficult, perhaps because <italic>M. tuberculosis</italic> is more sensitive to overexpression of PknB than <italic>M. smegmatis.</italic> Even a modest increase in PknB expression was sufficient to slow growth and alter cell morphology, and the effect of overexpression on inhibitor sensitivity was not significant (K.E.A. Lougheed, unpublished data).</p>
      <p>It is also possible that PknB may not be bound by the inhibitors when it is in a physiologically relevant configuration. In other drug discovery efforts, it has been shown that small molecule inhibitors are ineffective when their targets are involved in protein–protein interactions.<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> Such signalling complexes may behave differently in cells than in solution perhaps because the binding site is masked by interacting proteins or because of differences in the <italic>in vivo</italic> protein conformation compared to the purified protein against which the inhibitors were screened.</p>
      <p>Although <italic>pknB</italic> is an essential gene, very low levels of activity may be sufficient for survival, especially under the conditions we used to test our compounds. The <italic>M. tuberculosis</italic> kinases do display some redundancy, at least in the <italic>in vitro</italic> screens which have been used to investigate the substrates of the kinases. It is also possible that the cross-reactivity of the inhibitors against other kinases or the binding of alternative proteins results in a sequestering of the available inhibitor away from PknB. In fact, our results have demonstrated that the majority of the inhibitors tested are also able to inhibit PknF <italic>in vitro</italic>, although PknG was not as strongly inhibited. Ideally, a more specific inhibitor would need to be developed that could completely inhibit PknB <italic>in vivo</italic> without its effects being diluted by off-target binding.</p>
      <p>Our work appears to have highlighted one of the difficulties associated with target-based drug discovery: namely, that screening a relatively small library of inhibitors <italic>in vitro</italic> regularly fails to yield compounds with potent <italic>in vivo</italic> activity. However, the suitability of PknB as a drug target cannot yet be refuted. Our discovery of inhibitors with good <italic>in vitro</italic> activity and modest <italic>in vivo</italic> activity suggests that further screening on a larger scale may yet yield potent inhibitors able to completely inhibit the activity of PknB <italic>in vivo</italic>. To take into account the possibility of redundancy among the kinases, we believe further attempts to develop <italic>M. tuberculosis</italic> kinase inhibitors might usefully target a broad specificity inhibitor targeting multiple kinases as suggested by Hegymegi-Barakonyi et al.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref></p>
    </sec>
    <sec id="sec5">
      <title>Funding</title>
      <p>This work was supported by MRC Technology through a grant from the MRCT Development Gap Fund (A853-0058) and by the Medical Research Council (U117585867 and U117584228).</p>
    </sec>
    <sec id="sec6">
      <title>Competing interests</title>
      <p>None declared.</p>
    </sec>
    <sec id="sec7">
      <title>Ethical approval</title>
      <p>Not required.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bib1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>Global Alliance for TB Drug Development</collab>
          </person-group>
          <article-title>Tuberculosis. Scientific blueprint for tuberculosis drug development</article-title>
          <source>Tuberculosis (Edinb)</source>
          <volume>81</volume>
          <issue>Suppl. 1</issue>
          <year>2001</year>
          <fpage>1</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="pmid">11530398</pub-id>
        </element-citation>
      </ref>
      <ref id="bib2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lapenna</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Giordano</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Cell cycle kinases as therapeutic targets for cancer</article-title>
          <source>Nat Rev Drug Discov</source>
          <volume>8</volume>
          <year>2009</year>
          <fpage>547</fpage>
          <lpage>566</lpage>
          <pub-id pub-id-type="pmid">19568282</pub-id>
        </element-citation>
      </ref>
      <ref id="bib3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cole</surname>
              <given-names>S.T.</given-names>
            </name>
            <name>
              <surname>Brosch</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Parkhill</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Garnier</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Churcher</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Deciphering the biology of <italic>Mycobacterium tuberculosis</italic> from the complete genome sequence</article-title>
          <source>Nature</source>
          <volume>393</volume>
          <year>1998</year>
          <fpage>537</fpage>
          <lpage>544</lpage>
          <pub-id pub-id-type="pmid">9634230</pub-id>
        </element-citation>
      </ref>
      <ref id="bib4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Av-Gay</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Everett</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The eukaryotic-like Ser/Thr protein kinases of <italic>Mycobacterium tuberculosis</italic></article-title>
          <source>Trends Microbiol</source>
          <volume>8</volume>
          <year>2000</year>
          <fpage>238</fpage>
          <lpage>244</lpage>
          <pub-id pub-id-type="pmid">10785641</pub-id>
        </element-citation>
      </ref>
      <ref id="bib5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Narayan</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sachdeva</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Saini</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Tyagi</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Serine threonine protein kinases of mycobacterial genus: phylogeny to function</article-title>
          <source>Physiol Genomics</source>
          <volume>29</volume>
          <year>2007</year>
          <fpage>66</fpage>
          <lpage>75</lpage>
          <pub-id pub-id-type="pmid">17148687</pub-id>
        </element-citation>
      </ref>
      <ref id="bib6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Molle</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Kremer</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Division and cell envelope regulation by Ser/Thr phosphorylation: <italic>Mycobacterium</italic> shows the way</article-title>
          <source>Mol Microbiol</source>
          <volume>75</volume>
          <year>2010</year>
          <fpage>1064</fpage>
          <lpage>1077</lpage>
          <pub-id pub-id-type="pmid">20487298</pub-id>
        </element-citation>
      </ref>
      <ref id="bib7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eiglmeier</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Parkhill</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Honore</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Garnier</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Tekaia</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Telenti</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>The decaying genome of <italic>Mycobacterium leprae</italic></article-title>
          <source>Lepr Rev</source>
          <volume>72</volume>
          <year>2001</year>
          <fpage>387</fpage>
          <lpage>398</lpage>
          <pub-id pub-id-type="pmid">11826475</pub-id>
        </element-citation>
      </ref>
      <ref id="bib8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fernandez</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Saint-Joanis</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Barilone</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gicquel</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Cole</surname>
              <given-names>S.T.</given-names>
            </name>
          </person-group>
          <article-title>The Ser/Thr protein kinase PknB is essential for sustaining mycobacterial growth</article-title>
          <source>J Bacteriol</source>
          <volume>188</volume>
          <year>2006</year>
          <fpage>7778</fpage>
          <lpage>7784</lpage>
          <pub-id pub-id-type="pmid">16980473</pub-id>
        </element-citation>
      </ref>
      <ref id="bib9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sassetti</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Boyd</surname>
              <given-names>D.H.</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>E.J.</given-names>
            </name>
          </person-group>
          <article-title>Genes required for mycobacterial growth defined by high density mutagenesis</article-title>
          <source>Mol Microbiol</source>
          <volume>48</volume>
          <year>2003</year>
          <fpage>77</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="pmid">12657046</pub-id>
        </element-citation>
      </ref>
      <ref id="bib10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kang</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Abbott</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>S.T.</given-names>
            </name>
            <name>
              <surname>Dascher</surname>
              <given-names>C.C.</given-names>
            </name>
            <name>
              <surname>Cantley</surname>
              <given-names>L.C.</given-names>
            </name>
            <name>
              <surname>Husson</surname>
              <given-names>R.N.</given-names>
            </name>
          </person-group>
          <article-title>The <italic>Mycobacterium tuberculosis</italic> serine/threonine kinases PknA and PknB: substrate identification and regulation of cell shape</article-title>
          <source>Genes Dev</source>
          <volume>19</volume>
          <year>2005</year>
          <fpage>1692</fpage>
          <lpage>1704</lpage>
          <pub-id pub-id-type="pmid">15985609</pub-id>
        </element-citation>
      </ref>
      <ref id="bib11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cowley</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ko</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Pick</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Chow</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Downing</surname>
              <given-names>K.J.</given-names>
            </name>
            <name>
              <surname>Gordhan</surname>
              <given-names>B.G.</given-names>
            </name>
          </person-group>
          <article-title>The <italic>Mycobacterium tuberculosis</italic> protein serine/threonine kinase PknG is linked to cellular glutamate/glutamine levels and is important for growth in vivo</article-title>
          <source>Mol Microbiol</source>
          <volume>52</volume>
          <year>2004</year>
          <fpage>1691</fpage>
          <lpage>1702</lpage>
          <pub-id pub-id-type="pmid">15186418</pub-id>
        </element-citation>
      </ref>
      <ref id="bib12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walburger</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Koul</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ferrari</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Prescianotto-Baschong</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Huygen</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase G from pathogenic mycobacteria promotes survival within macrophages</article-title>
          <source>Science</source>
          <volume>304</volume>
          <year>2004</year>
          <fpage>1800</fpage>
          <lpage>1804</lpage>
          <pub-id pub-id-type="pmid">15155913</pub-id>
        </element-citation>
      </ref>
      <ref id="bib13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hegymegi-Barakonyi</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Szekely</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Varga</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Kiss</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Borbely</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Nemeth</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Signalling inhibitors against <italic>Mycobacterium tuberculosis</italic> - early days of a new therapeutic concept in tuberculosis</article-title>
          <source>Curr Med Chem</source>
          <volume>15</volume>
          <year>2008</year>
          <fpage>2760</fpage>
          <lpage>2770</lpage>
          <pub-id pub-id-type="pmid">18991635</pub-id>
        </element-citation>
      </ref>
      <ref id="bib14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Szekely</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Waczek</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Szabadkai</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Nemeth</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Hegymegi-Barakonyi</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Eros</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling</article-title>
          <source>Immunol Lett</source>
          <volume>116</volume>
          <year>2008</year>
          <fpage>225</fpage>
          <lpage>231</lpage>
          <pub-id pub-id-type="pmid">18258308</pub-id>
        </element-citation>
      </ref>
      <ref id="bib15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Young</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Delagoutte</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Endrizzi</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Falick</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Alber</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Structure of <italic>Mycobacterium tuberculosis</italic> PknB supports a universal activation mechanism for Ser/Thr protein kinases</article-title>
          <source>Nat Struct Biol</source>
          <volume>10</volume>
          <year>2003</year>
          <fpage>168</fpage>
          <lpage>174</lpage>
          <pub-id pub-id-type="pmid">12548283</pub-id>
        </element-citation>
      </ref>
      <ref id="bib16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ortiz-Lombardia</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Pompeo</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Boitel</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Alzari</surname>
              <given-names>P.M.</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of the catalytic domain of the PknB serine/threonine kinase from <italic>Mycobacterium tuberculosis</italic></article-title>
          <source>J Biol Chem</source>
          <volume>278</volume>
          <year>2003</year>
          <fpage>13094</fpage>
          <lpage>13100</lpage>
          <pub-id pub-id-type="pmid">12551895</pub-id>
        </element-citation>
      </ref>
      <ref id="bib17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Veyron-Churlet</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Zanella-Cleon</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Cohen-Gonsaud</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Molle</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Kremer</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Phosphorylation of the <italic>Mycobacterium tuberculosis</italic> beta-ketoacyl-acyl carrier protein reductase MabA regulates mycolic acid biosynthesis</article-title>
          <source>J Biol Chem</source>
          <volume>285</volume>
          <year>2010</year>
          <fpage>12714</fpage>
          <lpage>12725</lpage>
          <pub-id pub-id-type="pmid">20178986</pub-id>
        </element-citation>
      </ref>
      <ref id="bib18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parikh</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Verma</surname>
              <given-names>S.K.</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Prakash</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Nandicoori</surname>
              <given-names>V.K.</given-names>
            </name>
          </person-group>
          <article-title>PknB-mediated phosphorylation of a novel substrate, N-acetylglucosamine-1-phosphate uridyltransferase, modulates its acetyltransferase activity</article-title>
          <source>J Mol Biol</source>
          <volume>386</volume>
          <year>2009</year>
          <fpage>451</fpage>
          <lpage>464</lpage>
          <pub-id pub-id-type="pmid">19121323</pub-id>
        </element-citation>
      </ref>
      <ref id="bib19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Villarino</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Duran</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Wehenkel</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Fernandez</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>England</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Brodin</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Proteomic identification of <italic>M. tuberculosis</italic> protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions</article-title>
          <source>J Mol Biol</source>
          <volume>350</volume>
          <year>2005</year>
          <fpage>953</fpage>
          <lpage>963</lpage>
          <pub-id pub-id-type="pmid">15978616</pub-id>
        </element-citation>
      </ref>
      <ref id="bib20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O’Hare</surname>
              <given-names>H.M.</given-names>
            </name>
            <name>
              <surname>Duran</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Cervenansky</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Bellinzoni</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Wehenkel</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Pritsch</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <article-title>Regulation of glutamate metabolism by protein kinases in mycobacteria</article-title>
          <source>Mol Microbiol</source>
          <volume>70</volume>
          <year>2008</year>
          <fpage>1408</fpage>
          <lpage>1423</lpage>
          <pub-id pub-id-type="pmid">19019160</pub-id>
        </element-citation>
      </ref>
      <ref id="bib21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Carvalho</surname>
              <given-names>L.P.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Dickinson</surname>
              <given-names>C.E.</given-names>
            </name>
            <name>
              <surname>Arango</surname>
              <given-names>N.M.</given-names>
            </name>
            <name>
              <surname>Lima</surname>
              <given-names>C.D.</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>S.M.</given-names>
            </name>
          </person-group>
          <article-title>Activity-based metabolomic profiling of enzymatic function: identification of Rv1248c as a mycobacterial 2-hydroxy-3-oxoadipate synthase</article-title>
          <source>Chem Biol</source>
          <volume>17</volume>
          <year>2010</year>
          <fpage>323</fpage>
          <lpage>332</lpage>
          <pub-id pub-id-type="pmid">20416504</pub-id>
        </element-citation>
      </ref>
      <ref id="bib22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nott</surname>
              <given-names>T.J.</given-names>
            </name>
            <name>
              <surname>Kelly</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Stach</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Westcott</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>An intramolecular switch regulates phosphoindependent FHA domain interactions in <italic>Mycobacterium tuberculosis</italic></article-title>
          <source>Sci Signal</source>
          <volume>2</volume>
          <year>2009</year>
          <comment>ra12</comment>
        </element-citation>
      </ref>
      <ref id="bib23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>T.D.</given-names>
            </name>
            <name>
              <surname>Oldenburg</surname>
              <given-names>K.R.</given-names>
            </name>
          </person-group>
          <article-title>A simple statistical parameter for use in evaluation and validation of high throughput screening assays</article-title>
          <source>J Biomol Screen</source>
          <volume>4</volume>
          <year>1999</year>
          <fpage>67</fpage>
          <lpage>73</lpage>
          <pub-id pub-id-type="pmid">10838414</pub-id>
        </element-citation>
      </ref>
      <ref id="bib24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Collins</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Franzblau</surname>
              <given-names>S.G.</given-names>
            </name>
          </person-group>
          <article-title>Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against <italic>Mycobacterium tuberculosis</italic> and <italic>Mycobacterium avium</italic></article-title>
          <source>Antimicrob Agents Chemother</source>
          <volume>41</volume>
          <year>1997</year>
          <fpage>1004</fpage>
          <lpage>1009</lpage>
          <pub-id pub-id-type="pmid">9145860</pub-id>
        </element-citation>
      </ref>
      <ref id="bib25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lougheed</surname>
              <given-names>K.E.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>D.L.</given-names>
            </name>
            <name>
              <surname>Osborne</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Bryans</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Buxton</surname>
              <given-names>R.S.</given-names>
            </name>
          </person-group>
          <article-title>New anti-tuberculosis agents amongst known drugs</article-title>
          <source>Tuberculosis (Edinb)</source>
          <volume>89</volume>
          <year>2009</year>
          <fpage>364</fpage>
          <lpage>370</lpage>
          <pub-id pub-id-type="pmid">19699151</pub-id>
        </element-citation>
      </ref>
      <ref id="bib26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bain</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Plater</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Shpiro</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Hastie</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>McLauchlan</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>The selectivity of protein kinase inhibitors: a further update</article-title>
          <source>Biochem J</source>
          <volume>408</volume>
          <year>2007</year>
          <fpage>297</fpage>
          <lpage>315</lpage>
          <pub-id pub-id-type="pmid">17850214</pub-id>
        </element-citation>
      </ref>
      <ref id="bib27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>England</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Wehenkel</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Martins</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hoos</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Andre-Leroux</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Villarino</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>The FHA-containing protein GarA acts as a phosphorylation-dependent molecular switch in mycobacterial signaling</article-title>
          <source>FEBS Lett</source>
          <volume>583</volume>
          <year>2009</year>
          <fpage>301</fpage>
          <lpage>307</lpage>
          <pub-id pub-id-type="pmid">19114043</pub-id>
        </element-citation>
      </ref>
      <ref id="bib28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cheng</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Prusoff</surname>
              <given-names>W.H.</given-names>
            </name>
          </person-group>
          <article-title>Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction</article-title>
          <source>Biochem Pharmacol</source>
          <volume>22</volume>
          <year>1973</year>
          <fpage>3099</fpage>
          <lpage>3108</lpage>
          <pub-id pub-id-type="pmid">4202581</pub-id>
        </element-citation>
      </ref>
      <ref id="bib29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andries</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Verhasselt</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Guillemont</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Gohlmann</surname>
              <given-names>H.W.</given-names>
            </name>
            <name>
              <surname>Neefs</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Winkler</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>A diarylquinoline drug active on the ATP synthase of <italic>Mycobacterium tuberculosis</italic></article-title>
          <source>Science</source>
          <volume>307</volume>
          <year>2005</year>
          <fpage>223</fpage>
          <lpage>227</lpage>
          <pub-id pub-id-type="pmid">15591164</pub-id>
        </element-citation>
      </ref>
      <ref id="bib30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brennan</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Nikaido</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>The envelope of mycobacteria</article-title>
          <source>Annu Rev Biochem</source>
          <volume>64</volume>
          <year>1995</year>
          <fpage>29</fpage>
          <lpage>63</lpage>
          <pub-id pub-id-type="pmid">7574484</pub-id>
        </element-citation>
      </ref>
      <ref id="bib31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Malaviya</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gomes</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Enhanced biotransformation of sitosterol to androstenedione by <italic>Mycobacterium</italic> sp. using cell wall permeabilizing antibiotics</article-title>
          <source>J Ind Microbiol Biotechnol</source>
          <volume>35</volume>
          <year>2008</year>
          <fpage>1235</fpage>
          <lpage>1239</lpage>
          <pub-id pub-id-type="pmid">18716814</pub-id>
        </element-citation>
      </ref>
      <ref id="bib32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rastogi</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Goh</surname>
              <given-names>K.S.</given-names>
            </name>
            <name>
              <surname>David</surname>
              <given-names>H.L.</given-names>
            </name>
          </person-group>
          <article-title>Enhancement of drug susceptibility of <italic>Mycobacterium avium</italic> by inhibitors of cell envelope synthesis</article-title>
          <source>Antimicrob Agents Chemother</source>
          <volume>34</volume>
          <year>1990</year>
          <fpage>759</fpage>
          <lpage>764</lpage>
          <pub-id pub-id-type="pmid">2360816</pub-id>
        </element-citation>
      </ref>
      <ref id="bib33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jagannath</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Reddy</surname>
              <given-names>V.M.</given-names>
            </name>
            <name>
              <surname>Gangadharam</surname>
              <given-names>P.R.</given-names>
            </name>
          </person-group>
          <article-title>Enhancement of drug susceptibility of multi-drug resistant strains of <italic>Mycobacterium tuberculosis</italic> by ethambutol and dimethyl sulphoxide</article-title>
          <source>J Antimicrob Chemother</source>
          <volume>35</volume>
          <year>1995</year>
          <fpage>381</fpage>
          <lpage>390</lpage>
          <pub-id pub-id-type="pmid">7782254</pub-id>
        </element-citation>
      </ref>
      <ref id="bib34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Piddock</surname>
              <given-names>L.J.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>K.J.</given-names>
            </name>
            <name>
              <surname>Ricci</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <article-title>Accumulation of rifampicin by <italic>Mycobacterium aurum, Mycobacterium smegmatis</italic> and <italic>Mycobacterium tuberculosis</italic></article-title>
          <source>J Antimicrob Chemother</source>
          <volume>45</volume>
          <year>2000</year>
          <fpage>159</fpage>
          <lpage>165</lpage>
          <pub-id pub-id-type="pmid">10660497</pub-id>
        </element-citation>
      </ref>
      <ref id="bib35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nguyen</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Chinnapapagari</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>C.J.</given-names>
            </name>
          </person-group>
          <article-title>FbpA-Dependent biosynthesis of trehalose dimycolate is required for the intrinsic multidrug resistance, cell wall structure, and colonial morphology of <italic>Mycobacterium smegmatis</italic></article-title>
          <source>J Bacteriol</source>
          <volume>187</volume>
          <year>2005</year>
          <fpage>6603</fpage>
          <lpage>6611</lpage>
          <pub-id pub-id-type="pmid">16166521</pub-id>
        </element-citation>
      </ref>
      <ref id="bib36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lambert</surname>
              <given-names>P.A.</given-names>
            </name>
          </person-group>
          <article-title>Cellular impermeability and uptake of biocides and antibiotics in Gram-positive bacteria and mycobacteria</article-title>
          <source>J Appl Microbiol</source>
          <volume>92</volume>
          <issue>Suppl.</issue>
          <year>2002</year>
          <fpage>46S</fpage>
          <lpage>54S</lpage>
          <pub-id pub-id-type="pmid">12000612</pub-id>
        </element-citation>
      </ref>
      <ref id="bib37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stephan</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Mailaender</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Etienne</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Daffe</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Niederweis</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Multidrug resistance of a porin deletion mutant of <italic>Mycobacterium smegmatis</italic></article-title>
          <source>Antimicrob Agents Chemother</source>
          <volume>48</volume>
          <year>2004</year>
          <fpage>4163</fpage>
          <lpage>4170</lpage>
          <pub-id pub-id-type="pmid">15504836</pub-id>
        </element-citation>
      </ref>
      <ref id="bib38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mailaender</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Reiling</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Engelhardt</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Bossmann</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ehlers</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Niederweis</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The MspA porin promotes growth and increases antibiotic susceptibility of both <italic>Mycobacterium bovis</italic> BCG and <italic>Mycobacterium tuberculosis</italic></article-title>
          <source>Microbiology</source>
          <volume>150</volume>
          <year>2004</year>
          <fpage>853</fpage>
          <lpage>864</lpage>
          <pub-id pub-id-type="pmid">15073295</pub-id>
        </element-citation>
      </ref>
      <ref id="bib39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Siroy</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Mailaender</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Harder</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Koerber</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Wolschendorf</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Danilchanka</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <article-title>Rv1698 of <italic>Mycobacterium tuberculosis</italic> represents a new class of channel-forming outer membrane proteins</article-title>
          <source>J Biol Chem</source>
          <volume>283</volume>
          <year>2008</year>
          <fpage>17827</fpage>
          <lpage>17837</lpage>
          <pub-id pub-id-type="pmid">18434314</pub-id>
        </element-citation>
      </ref>
      <ref id="bib40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Raynaud</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Laneelle</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Senaratne</surname>
              <given-names>R.H.</given-names>
            </name>
            <name>
              <surname>Draper</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Laneelle</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Daffe</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity</article-title>
          <source>Microbiology</source>
          <volume>145</volume>
          <year>1999</year>
          <fpage>1359</fpage>
          <lpage>1367</lpage>
          <pub-id pub-id-type="pmid">10411262</pub-id>
        </element-citation>
      </ref>
      <ref id="bib41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takiff</surname>
              <given-names>H.E.</given-names>
            </name>
            <name>
              <surname>Cimino</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Musso</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Weisbrod</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Martinez</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Delgado</surname>
              <given-names>M.B.</given-names>
            </name>
          </person-group>
          <article-title>Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in <italic>Mycobacterium smegmatis</italic></article-title>
          <source>Proc Natl Acad Sci USA</source>
          <volume>93</volume>
          <year>1996</year>
          <fpage>362</fpage>
          <lpage>366</lpage>
          <pub-id pub-id-type="pmid">8552639</pub-id>
        </element-citation>
      </ref>
      <ref id="bib42">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gupta</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Chauhan</surname>
              <given-names>D.S.</given-names>
            </name>
            <name>
              <surname>Srivastava</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Das</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Batra</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Mittal</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Estimation of efflux mediated multi-drug resistance and its correlation with expression levels of two major efflux pumps in mycobacteria</article-title>
          <source>J Commun Dis</source>
          <volume>38</volume>
          <year>2006</year>
          <fpage>246</fpage>
          <lpage>254</lpage>
          <pub-id pub-id-type="pmid">17373356</pub-id>
        </element-citation>
      </ref>
      <ref id="bib43">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Escribano</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Llorca</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Garcia-Pachon</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Ruiz</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Royo</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Importance of the efflux pump systems in the resistance of <italic>Mycobacterium tuberculosis</italic> to fluoroquinolones and linezolid</article-title>
          <source>Chemotherapy</source>
          <volume>53</volume>
          <year>2007</year>
          <fpage>397</fpage>
          <lpage>401</lpage>
          <pub-id pub-id-type="pmid">17934259</pub-id>
        </element-citation>
      </ref>
      <ref id="bib44">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Srivastava</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Musuka</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Sherman</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Meek</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Leff</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Gumbo</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in <italic>Mycobacterium tuberculosis</italic> and the pharmacokinetics and pharmacodynamics of ethambutol</article-title>
          <source>J Infect Dis</source>
          <volume>201</volume>
          <year>2010</year>
          <fpage>1225</fpage>
          <lpage>1231</lpage>
          <pub-id pub-id-type="pmid">20210628</pub-id>
        </element-citation>
      </ref>
      <ref id="bib45">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amaral</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Martins</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Viveiros</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Enhanced killing of intracellular multidrug-resistant <italic>Mycobacterium tuberculosis</italic> by compounds that affect the activity of efflux pumps</article-title>
          <source>J Antimicrob Chemother</source>
          <volume>59</volume>
          <year>2007</year>
          <fpage>1237</fpage>
          <lpage>1246</lpage>
          <pub-id pub-id-type="pmid">17218448</pub-id>
        </element-citation>
      </ref>
      <ref id="bib46">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramon-Garcia</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>De Rossi</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Ainsa</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Contribution of the Rv2333c efflux pump (the Stp protein) from <italic>Mycobacterium tuberculosis</italic> to intrinsic antibiotic resistance in <italic>Mycobacterium bovis</italic> BCG</article-title>
          <source>J Antimicrob Chemother</source>
          <volume>59</volume>
          <year>2007</year>
          <fpage>544</fpage>
          <lpage>547</lpage>
          <pub-id pub-id-type="pmid">17242035</pub-id>
        </element-citation>
      </ref>
      <ref id="bib47">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramon-Garcia</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Ainsa</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Role of the <italic>Mycobacterium tuberculosis</italic> P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth</article-title>
          <source>Antimicrob Agents Chemother</source>
          <volume>53</volume>
          <year>2009</year>
          <fpage>3675</fpage>
          <lpage>3682</lpage>
          <pub-id pub-id-type="pmid">19564371</pub-id>
        </element-citation>
      </ref>
      <ref id="bib48">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>X.Z.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Nikaido</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Efflux pump-mediated intrinsic drug resistance in <italic>Mycobacterium smegmatis</italic></article-title>
          <source>Antimicrob Agents Chemother</source>
          <volume>48</volume>
          <year>2004</year>
          <fpage>2415</fpage>
          <lpage>2423</lpage>
          <pub-id pub-id-type="pmid">15215089</pub-id>
        </element-citation>
      </ref>
      <ref id="bib49">
        <label>49</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Singh</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Pine</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Chandra</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Drlica</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase I of <italic>Mycobacterium tuberculosis</italic>: cellular localization and expression during infection of macrophage-like cells</article-title>
          <source>Tuberculosis (Edinb)</source>
          <volume>86</volume>
          <year>2006</year>
          <fpage>28</fpage>
          <lpage>33</lpage>
          <pub-id pub-id-type="pmid">16256441</pub-id>
        </element-citation>
      </ref>
      <ref id="bib50">
        <label>50</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koul</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Vranckx</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Dendouga</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Balemans</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Van den Wyngaert</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Vergauwen</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis</article-title>
          <source>J Biol Chem</source>
          <volume>283</volume>
          <year>2008</year>
          <fpage>25273</fpage>
          <lpage>25280</lpage>
          <pub-id pub-id-type="pmid">18625705</pub-id>
        </element-citation>
      </ref>
      <ref id="bib51">
        <label>51</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Payne</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Gwynn</surname>
              <given-names>M.N.</given-names>
            </name>
            <name>
              <surname>Holmes</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Pompliano</surname>
              <given-names>D.L.</given-names>
            </name>
          </person-group>
          <article-title>Drugs for bad bugs: confronting the challenges of antibacterial discovery</article-title>
          <source>Nat Rev Drug Discov</source>
          <volume>6</volume>
          <year>2007</year>
          <fpage>29</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="pmid">17159923</pub-id>
        </element-citation>
      </ref>
      <ref id="bib52">
        <label>52</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoshi</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Langeberg</surname>
              <given-names>L.K.</given-names>
            </name>
            <name>
              <surname>Gould</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Newton</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>J.D.</given-names>
            </name>
          </person-group>
          <article-title>Interaction with AKAP79 modifies the cellular pharmacology of PKC</article-title>
          <source>Mol Cell</source>
          <volume>37</volume>
          <year>2010</year>
          <fpage>541</fpage>
          <lpage>550</lpage>
          <pub-id pub-id-type="pmid">20188672</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <ack>
      <title>Acknowledgements</title>
      <p>We thank Kristian Birchall for providing <xref rid="fig1" ref-type="fig">Figure 1</xref>, Charles Thompson for the gift of the <italic>fbpA</italic> mutant, Philip Draper for the <italic>ompA</italic> mutant, and Elaine Davis for helpful discussions.</p>
    </ack>
  </back>
  <floats-group>
    <fig id="fig1">
      <label>Figure 1</label>
      <caption>
        <p>Docking of MRCT67127 into PknB active site. Green ribbon represents PknB (Code: 1MRU) with ATP co-crystallised (shown as green structure). Grey ribbon represents PknB (Code: 2FUM) with mitoxantrone co-crystallised. The mitoxantrone structure was removed and docking studies conducted with this PknB conformation: owing to the flat nature of the docked compounds (making them similar to mitoxantrone), this was considered a better way to obtain reliable results. MRT67127 is shown (grey structure) docked into PknB.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="fig2">
      <label>Figure 2</label>
      <caption>
        <p>Compounds inactive against <italic>M. tuberculosis</italic> had a range of IC<sub>50</sub>s against the purified protein. A similar spread was observed for the compounds able to inhibit <italic>M. tuberculosis</italic>. Starred section indicated the area of the graph where compounds highly active against both the purified protein and whole cells would appear.</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
    <fig id="fig3">
      <label>Figure 3</label>
      <caption>
        <p>Intracellular activity of PknB inhibitors in a bone marrow derived macrophage model. Macrophages were infected with an MOI of 0.5:1 and incubated in the presence of a dilution series of the inhibitors. After 5 days, the macrophages were lysed and the intracellular bacteria enumerated by CFU platings. Data is expressed as percentage survival compared to the untreated control. Inhibitor structures and corresponding <italic>in vitro</italic> activity against purified protein are shown in <xref rid="tbl1" ref-type="table">Table 1</xref>.</p>
      </caption>
      <graphic xlink:href="gr3"/>
    </fig>
    <fig id="fig4">
      <label>Figure 4</label>
      <caption>
        <p><italic>In vitro</italic> activity of the PknB inhibitors against PknF and PknG. The inhibitors were tested at 1 μM (not shown) and 10 μM for their ability to inhibit PknB, PknF and PknG in an autophosphorylation assay. There was good agreement between the anti-PknB activity in this assay and the non-radioactive assay used in the high throughput screen. The graph was created using the averaged band intensities from three independent autoradiographs.</p>
      </caption>
      <graphic xlink:href="gr4"/>
    </fig>
    <table-wrap id="tbl1" position="float">
      <label>Table 1</label>
      <caption>
        <p>Structures and inhibitor activity against purified PknB and <italic>M. tuberculosis</italic> in an Alamar blue and an intracellular assay. IC<sub>50</sub> is shown as the mean of three experimental repeats, Alamar blue and intracellular MIC is representative of three or more repeats.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th>Inhibitor</th>
            <th>Structure</th>
            <th>IC<sub>50</sub> PknB μM</th>
            <th>MIC <italic>M. tuberculosis</italic> μM<xref rid="tbl1fnlowast" ref-type="table-fn">∗</xref></th>
            <th>MIC Intracellular μM<xref rid="tbl1fndagger" ref-type="table-fn">†</xref></th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td>1.MRT67127</td>
            <td>
              <inline-graphic xlink:href="fx1.gif"/>
            </td>
            <td align="char">0.053</td>
            <td align="char">32</td>
            <td align="char">5</td>
          </tr>
          <tr>
            <td>2.MRT67153</td>
            <td>
              <inline-graphic xlink:href="fx2.gif"/>
            </td>
            <td align="char">0.056</td>
            <td align="char">32</td>
            <td align="char">20</td>
          </tr>
          <tr>
            <td>3.MRT68667</td>
            <td>
              <inline-graphic xlink:href="fx3.gif"/>
            </td>
            <td align="char">0.09</td>
            <td align="char">64</td>
            <td align="char">20</td>
          </tr>
          <tr>
            <td>4.MRT68606</td>
            <td>
              <inline-graphic xlink:href="fx4.gif"/>
            </td>
            <td align="char">0.519</td>
            <td align="char">16</td>
            <td align="char">&gt;20</td>
          </tr>
          <tr>
            <td>5.MRT68572</td>
            <td>
              <inline-graphic xlink:href="fx5.gif"/>
            </td>
            <td align="char">16.554</td>
            <td align="char">16</td>
            <td align="char">&gt;20</td>
          </tr>
          <tr>
            <td>6.MRT68634</td>
            <td>
              <inline-graphic xlink:href="fx6.gif"/>
            </td>
            <td align="char">1.499</td>
            <td align="char">64</td>
            <td align="char">&gt;20</td>
          </tr>
          <tr>
            <td>7.MRT67131</td>
            <td>
              <inline-graphic xlink:href="fx7.gif"/>
            </td>
            <td align="char">0.345</td>
            <td align="char">125</td>
            <td align="char">&gt;20</td>
          </tr>
          <tr>
            <td>8.MRT67150</td>
            <td>
              <inline-graphic xlink:href="fx8.gif"/>
            </td>
            <td align="char">0.055</td>
            <td align="char">32</td>
            <td align="char">5</td>
          </tr>
          <tr>
            <td>9.MRT67155</td>
            <td>
              <inline-graphic xlink:href="fx9.gif"/>
            </td>
            <td align="char">0.096</td>
            <td align="char">64</td>
            <td align="char">10</td>
          </tr>
          <tr>
            <td>10.MRT67156</td>
            <td>
              <inline-graphic xlink:href="fx10.gif"/>
            </td>
            <td align="char">0.092</td>
            <td align="char">16</td>
            <td align="char">5</td>
          </tr>
          <tr>
            <td>11.MRT67319</td>
            <td>
              <inline-graphic xlink:href="fx11.gif"/>
            </td>
            <td align="char">6.194</td>
            <td align="char">32</td>
            <td align="char">10</td>
          </tr>
          <tr>
            <td>12.MRT68664</td>
            <td>
              <inline-graphic xlink:href="fx12.gif"/>
            </td>
            <td align="char">0.065</td>
            <td align="char">64</td>
            <td align="char">5</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tbl1fnlowast">
          <label>*</label>
          <p>90% inhibition fluorescence compared to untreated control.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tbl1fndagger">
          <label>†</label>
          <p>99% inhibition compared to untreated control.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>